{"doi":"10.1016/j.clon.2018.01.003","title":"Hyperglycaemia and Survival in Solid Tumours: A Systematic Review and Meta-analysis","abstract":null,"journal":"Clinical Oncology","year":2018,"id":688858,"datarank":0.5837730447165941,"base_score":3.8918202981106265,"endowment":3.8918202981106265,"self_citation_contribution":0.5837730447165941,"citation_network_contribution":0.0,"self_endowment_contribution":0.5837730447165941,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":48,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1799637,"name":"A.J. Templeton","orcid":null,"position":1,"is_corresponding":false},{"id":1799638,"name":"B. Seruga","orcid":null,"position":2,"is_corresponding":false},{"id":1799639,"name":"A. Ocana","orcid":null,"position":3,"is_corresponding":false},{"id":1799640,"name":"E. Amir","orcid":null,"position":4,"is_corresponding":false},{"id":956956,"name":"Josée-Lyne Ethier","orcid":"0000-0003-0711-1021","position":5,"is_corresponding":false},{"id":1799636,"name":"R. Barua","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Hyperglycaemia and Survival in Solid Tumours: A Systematic Review and Meta-analysis","abstract":"<h4>Aims</h4>Diabetes is associated with adverse cancer outcomes. However, the effect of hyperglycaemia in non-diabetic cancer patients is unclear.<h4>Materials and methods</h4>A systematic search of electronic databases identified publications exploring the effect of hyperglycaemia on overall survival, disease-free survival (DFS) or progression-free survival (PFS). Data from studies reporting a hazard ratio and 95% confidence interval and/or a P-value were pooled in a meta-analysis using generic inverse-variance and random effects modelling. Subgroup analyses were conducted based on method of hyperglycaemia measurement (HbA1c, other) and stage (early, advanced, mixed). Meta-regression was performed to evaluate the influence of clinical characteristics including baseline diabetes status on the hazard ratio for overall survival.<h4>Results</h4>Twelve studies comprising a total of 9872 patients were included. All studies reported hazard ratios for overall survival. Three studies reported DFS; two reported PFS outcomes. Definitions of hyperglycaemia and cut-offs varied between studies. Hyperglycaemia was associated with worse overall survival (hazard ratio 2.05, 95% confidence interval 1.67-2.51; P < 0.001) and DFS (hazard ratio 1.98, 95% confidence interval 1.20-3.27; P = 0.007), but did not affect PFS (hazard ratio 1.08, 95% confidence interval 0.72-1.62; P = 0.71). The association with worse overall survival was maintained in subgroups based on method of hyperglycaemia measurement (subgroup difference P = 0.46) and stage (P = 0.14). Meta-regression showed a significantly greater magnitude of association between hyperglycaemia and decreased overall survival in studies with higher proportions of women and diabetic patients.<h4>Conclusions</h4>Hyperglycaemia is associated with adverse overall survival and DFS in patients with cancer. The therapeutic role of glycaemic control in cancer patients warrants further investigation.","is_dataset_classified":null,"base_score":3.8918202981106265,"endowment":3.8918202981106265,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"29395413","pmcid":null,"openalex_id":"https://openalex.org/W2786720589","authors":[],"funders":[],"total_grants":0,"fwci":1.4351,"citation_percentile":0.77991747,"influential_citations":0,"citation_trend":[{"year":2018,"count":2},{"year":2019,"count":6},{"year":2020,"count":5},{"year":2021,"count":4},{"year":2022,"count":5},{"year":2023,"count":7},{"year":2024,"count":7},{"year":2025,"count":7},{"year":2026,"count":5}],"oa_status":"closed","license":"https://www.elsevier.com/legal/tdmrep-license","oa_locations":[{"url":"https://api.elsevier.com/content/article/PII:S0936655518300050?httpAccept=text/xml","host_type":"publisher"},{"url":"https://api.elsevier.com/content/article/PII:S0936655518300050?httpAccept=text/plain","host_type":"publisher"},{"url":"https://doi.org/10.1016/j.clon.2018.01.003","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/29395413","host_type":"repository"}],"fields_of_study":["Metabolism, Diabetes, and Cancer","Cancer, Hypoxia, and Metabolism","Hyperglycemia and glycemic control in critically ill and hospitalized patients","Disease-Free Survival","Female","Humans","Hyperglycemia","Neoplasms","Prognosis","Proportional Hazards Models"],"mesh_terms":["Female","Humans","Hyperglycemia","Neoplasms","Prognosis","Proportional Hazards Models","Disease-Free Survival"],"keywords":["Medicine","Meta-analysis","Oncology","Intensive care medicine","MEDLINE","Internal medicine","Cancer","Survival","Diabetes","Hyperglycaemia"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-19T19:53:35.666793Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}